IIT2025-03-YANG-LIFT-HCC

Summary

The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.

Timeline

Start

2026-04-01

Primary completion

2030-04-01

Completion

2030-12-31

Drugs

Indications